6-Methyl-MDA

From Wikipedia, the free encyclopedia
Jump to: navigation, search
6-Methyl-MDA
6-Methyl-MDA.png
Systematic (IUPAC) name
1-(6-methyl-1,3-benzodioxol-5-yl)propan-2-amine
Clinical data
Routes of
administration
Oral
Legal status
Legal status
Identifiers
ATC code none
PubChem CID 10511982
ChemSpider 8687383 YesY
ChEMBL CHEMBL6376 YesY
Chemical data
Formula C11NO2
Molar mass 193.24 g/mol
  (verify)

6-Methyl-3,4-methylenedioxyamphetamine (6-Methyl-MDA) is an entactogen and psychedelic drug of the amphetamine class.[1] It was first synthesized in the late 1990s by a team including David E. Nichols at Purdue University while investigating derivatives of MDA and MDMA.[1]

6-Methyl-MDA has IC50 values of 783nM, 28,300nM, and 4,602nM for inhibiting the reuptake of serotonin, dopamine, and norepinephrine in rat synaptosomes.[1] In animal studies it substitutes for MBDB, MMAI, LSD, and DOI, though not amphetamine, but only partially and at high doses.[1] Thus, while several-fold less potent than its analogues 2-methyl-MDA and 5-methyl-MDA, and approximately half as potent as MDA, 6-methyl-MDA is still significantly active,[1] and appropriate doses may be similar to or somewhat higher than those of MDMA.[citation needed]

References[edit]

  1. ^ a b c d e Parker MA, Marona-Lewicka D, Kurrasch D, Shulgin AT, Nichols DE (March 1998). "Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA)". Journal of Medicinal Chemistry. 41 (6): 1001–5. doi:10.1021/jm9705925. PMID 9526575.